Comparison of different clinical features between PsA patients (n) in DAPSA LDA with and without RDA in the articular domain (tender joint), PRO (VAS pain and PtGA), and skin domain (PASI; Fisher’s exact test; categorical variables).
| Tender Joints | VAS Pain, mm | PtGA, mm | PASI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RDA+§ | RDA– | p | RDA+# | RDA– | p | RDA+° | RDA– | p | RDA+$ | RDA– | p | |
| Male | 16 | 46 | NS | 28 | 34 | NS | 16 | 46 | 0.04 | 21 | 40 | 0.01 |
| Female | 13 | 31 | 27 | 17 | 20 | 24 | 3 | 39 | ||||
| Axial involvement | 2 | 39 | NS | 25 | 16 | NS | 16 | 25 | NS | 6 | 33 | NS |
| No axial involvement | 6 | 56 | 20 | 42 | 19 | 43 | 17 | 44 | ||||
↵§ Tender joints RDA+: > 1.
↵# VAS pain RDA+: > 15 mm.
↵° PtGA RDA+: > 20 mm.
↵$ PASI RDA+: > 1. RDA: residual disease activity; PsA: psoriatic arthritis; DAPSA: Disease Activity Index for Psoriatic Arthritis; LDA: low disease activity; PASI: Psoriasis Area Severity Index; PRO: patient-reported outcome; PtGA: patient’s global assessment; VAS: visual analog scale; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; LEI: Leeds Enthesitis Index; IQR: interquartile range; NS: not significant.